Intellia Therapeutics, Inc. (NTLA) News
Filter NTLA News Items
NTLA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NTLA News Highlights
- NTLA's 30 day story count now stands at 8.
- Over the past 21 days, the trend for NTLA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- GENE, BEAM and EDIT are the most mentioned tickers in articles about NTLA.
Latest NTLA News From Around the Web
Below are the latest news stories about INTELLIA THERAPEUTICS INC that investors may wish to consider to help them evaluate NTLA as an investment opportunity.
13 Most Promising Future Stocks To Buy According To Hedge FundsIn this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. Investing, for the most part, is all […] |
5 Beaten-Down Stocks That Could Soar in 2024These players may offer your portfolio a lift as early as next year. But most importantly, they could excel over time. |
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeuticsbluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog. |
3 Gene-Editing Stocks With the Potential to Mint MillionairesGene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. |
3 Biotechs With Promising Gene Therapies in the SpotlightThe recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline. |
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?Intellia is approaching the finish line. |
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull MarketBuying shares of promising growth companies that haven't yet benefited from the rally is a terrific idea because, right now, you can pick up many of these players for a bargain. Teladoc Health's (NYSE: TDOC) revenue and number of visits soared in the triple digits in the early days of the pandemic as patients favored virtual medical visits over going to a doctor's office. Later into the health crisis though, Teladoc saw a slowdown in growth, and at the same time its purchase of Livongo, a chronic care specialist, set it back from its goal of profitability. |
Gene Editing Will Change Medicine—and Maybe Health Investing TooThe first treatment based on the Nobel Prize-winning Crispr technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors. |
Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE CandidateThe European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises. |
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary AngioedemaCAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-thre |